Takeda Submits Safety Data For Alogliptin To U.S FDA
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals announced July 28 it submitted additional information to U.S. FDA in April regarding the DPP-4 inhibitor SYR-322 (alogliptin) and in combination with Actos (pioglitazone).